FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016753076> ?p ?o ?g. }

• W2016753076 endingPage "762" @default.
• W2016753076 startingPage "756" @default.
• W2016753076 abstract "Summary Background In patients with multiple endocrine neoplasia type 1 (MEN1), expression of somatostatin receptor (SST) in parathyroid adenomas and effectiveness of therapy with somatostatin analogues on primary hyperparathyroidism (PHP) have been scarcely investigated. Objective To evaluate the effects of depot long acting octreotide (OCT‐LAR) in patients with MEN1‐related PHP. Patients Eight patients with a genetically confirmed MEN1, presenting both PHP and duodeno‐pancreatic neuroendocrine tumours (NET), were enrolled. Design The initial treatment was OCT‐LAR 30 mg every 4 weeks. This therapy was established to stabilize the duodeno‐pancreatic NET before to perform parathyroidectomy for PHP. Before OCT‐LAR therapy, a SST scintigraphy was performed in all patients. SST subtype 2A immunohistochemistry was performed on parathyroid tumour samples from three patients undergone parathyroidectomy after OCT‐LAR therapy. Measurements Serum concentrations of PTH, calcium and phosphorus as well as the 24‐h urine calcium : creatinine ratio and the renal threshold phosphate concentration were evaluated before and after OCT‐LAR. Results After OCT‐LAR therapy, hypercalcaemia and hypercalciuria normalized in 75% and 62·5% of patients, respectively, and serum phosphorus and renal threshold phosphate significantly increased. Serum PTH concentrations significantly decreased in all patients and normalized in two of them. SST subtype 2A immunostaining was found in all parathyroid adenomas investigated, while SST scintigraphy showed a positive parathyroid tumour uptake in three of eight patients (37·5%). Conclusion Six months of OCT‐LAR therapy controlled hypercalcaemia and hypercalciuria in two‐thirds of patients with MEN1‐related PHP. Direct OCT‐LAR effects mediated by binding to SST expression on parathyroid tumour cells are likely the main mechanism to explain the activity of this compound on calcium and phosphorus abnormalities in MEN1 PHP." @default.
• W2016753076 created "2016-06-24" @default.
• W2016753076 creator A5004588703 @default.
• W2016753076 creator A5012196997 @default.
• W2016753076 creator A5012683920 @default.
• W2016753076 creator A5021590158 @default.
• W2016753076 creator A5021797078 @default.
• W2016753076 creator A5025013672 @default.
• W2016753076 creator A5039934649 @default.
• W2016753076 creator A5070034601 @default.
• W2016753076 creator A5077499862 @default.
• W2016753076 creator A5087741902 @default.
• W2016753076 date "2008-10-14" @default.
• W2016753076 modified "2023-10-18" @default.
• W2016753076 title "Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients" @default.
• W2016753076 cites W1529179362 @default.
• W2016753076 cites W1965913464 @default.
• W2016753076 cites W1966746560 @default.
• W2016753076 cites W1975022308 @default.
• W2016753076 cites W1985845358 @default.
• W2016753076 cites W1990493826 @default.
• W2016753076 cites W2011478379 @default.
• W2016753076 cites W2026284633 @default.
• W2016753076 cites W2035944936 @default.
• W2016753076 cites W2050413914 @default.
• W2016753076 cites W2053578362 @default.
• W2016753076 cites W2064584518 @default.
• W2016753076 cites W2080232093 @default.
• W2016753076 cites W2083116747 @default.
• W2016753076 cites W2084039621 @default.
• W2016753076 cites W2085724145 @default.
• W2016753076 cites W2088693719 @default.
• W2016753076 cites W2136955490 @default.
• W2016753076 cites W2139998567 @default.
• W2016753076 cites W2160989555 @default.
• W2016753076 cites W2164614522 @default.
• W2016753076 cites W2291829517 @default.
• W2016753076 cites W2885436031 @default.
• W2016753076 doi "https://doi.org/10.1111/j.1365-2265.2008.03301.x" @default.
• W2016753076 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18485119" @default.
• W2016753076 hasPublicationYear "2008" @default.
• W2016753076 type Work @default.
• W2016753076 sameAs 2016753076 @default.
• W2016753076 citedByCount "28" @default.
• W2016753076 countsByYear W20167530762012 @default.
• W2016753076 countsByYear W20167530762013 @default.
• W2016753076 countsByYear W20167530762014 @default.
• W2016753076 countsByYear W20167530762015 @default.
• W2016753076 countsByYear W20167530762016 @default.
• W2016753076 countsByYear W20167530762017 @default.
• W2016753076 countsByYear W20167530762019 @default.
• W2016753076 countsByYear W20167530762021 @default.
• W2016753076 countsByYear W20167530762023 @default.
• W2016753076 crossrefType "journal-article" @default.
• W2016753076 hasAuthorship W2016753076A5004588703 @default.
• W2016753076 hasAuthorship W2016753076A5012196997 @default.
• W2016753076 hasAuthorship W2016753076A5012683920 @default.
• W2016753076 hasAuthorship W2016753076A5021590158 @default.
• W2016753076 hasAuthorship W2016753076A5021797078 @default.
• W2016753076 hasAuthorship W2016753076A5025013672 @default.
• W2016753076 hasAuthorship W2016753076A5039934649 @default.
• W2016753076 hasAuthorship W2016753076A5070034601 @default.
• W2016753076 hasAuthorship W2016753076A5077499862 @default.
• W2016753076 hasAuthorship W2016753076A5087741902 @default.
• W2016753076 hasBestOaLocation W20167530762 @default.
• W2016753076 hasConcept C104317684 @default.
• W2016753076 hasConcept C126322002 @default.
• W2016753076 hasConcept C126894567 @default.
• W2016753076 hasConcept C134018914 @default.
• W2016753076 hasConcept C185592680 @default.
• W2016753076 hasConcept C2775945674 @default.
• W2016753076 hasConcept C2776297358 @default.
• W2016753076 hasConcept C2777645128 @default.
• W2016753076 hasConcept C2777724520 @default.
• W2016753076 hasConcept C2779053571 @default.
• W2016753076 hasConcept C2779469564 @default.
• W2016753076 hasConcept C2779674975 @default.
• W2016753076 hasConcept C2780103800 @default.
• W2016753076 hasConcept C2781025020 @default.
• W2016753076 hasConcept C2781208988 @default.
• W2016753076 hasConcept C46699223 @default.
• W2016753076 hasConcept C519063684 @default.
• W2016753076 hasConcept C55493867 @default.
• W2016753076 hasConcept C71315377 @default.
• W2016753076 hasConcept C71924100 @default.
• W2016753076 hasConcept C90924648 @default.
• W2016753076 hasConceptScore W2016753076C104317684 @default.
• W2016753076 hasConceptScore W2016753076C126322002 @default.
• W2016753076 hasConceptScore W2016753076C126894567 @default.
• W2016753076 hasConceptScore W2016753076C134018914 @default.
• W2016753076 hasConceptScore W2016753076C185592680 @default.
• W2016753076 hasConceptScore W2016753076C2775945674 @default.
• W2016753076 hasConceptScore W2016753076C2776297358 @default.
• W2016753076 hasConceptScore W2016753076C2777645128 @default.
• W2016753076 hasConceptScore W2016753076C2777724520 @default.
• W2016753076 hasConceptScore W2016753076C2779053571 @default.
• W2016753076 hasConceptScore W2016753076C2779469564 @default.
• W2016753076 hasConceptScore W2016753076C2779674975 @default.

• next